Goodbody Health Ltd - Launch of mobile phlebotomy service
RNS Number : 1258T
Goodbody Health Limited
16 March 2023

16th March 2023

Goodbody Health Limited
("Goodbody Health", or the "Company")

Goodbody Health launches mobile phlebotomy service


Goodbody Health (AQSE: GDBY) is pleased to announce the expansion of services through partnerships and the launch of its new mobile phlebotomy service to develop and increase the reach of the phlebotomy services that Goodbody is able to offer. This allows testing to be undertaken in the patients home or other convenient location and meets the needs of those unable to travel. This has proven to be very successful with over 120 applicant phlebotomists for the platform and patients choosing this sample collection method. This sample collection method will be available for partners in the not-too-distant future. This is a significant piece of technology that has been developed over 4 months.


Following the Company announcement on January 26th, 2023, that it has partnered with Datar Cancer Genetics ("Datar"), a world-leading liquid biopsy company, to offer its innovative Circulating Tumour Cell ("CTC") based multi-cancer screening solution Trucheck, the rollout of these innovative tests has started to show good progress. The Company has had significant interest in the product through the initial soft-launch phase, demonstrating that this could be a significant revenue stream for the Company with 25 tests sold to date generating strong revenue. The Company has also established a distribution infrastructure to resell the tests to other private medical providers to drive additional volume and uptake has been positive.


Following the Company announcements on January 31st and February 15th, 2023, that the Company had signed phlebotomy contracts with 5 other testing suppliers who wish to use Goodbody Clinics as a phlebotomy partner, 4 more contracts have been signed with the following partners:


·    Balance My Hormones - Hormone Replacement Provider

·    Optimale - Hormone Replacement Provider

·    Manual - Blood and Wellness Testing provider

·    Cancer Screening Trust

George Thomas, Chief Executive Officer, said: "The Company is excited to develop new product opportunities, integrate with other providers and supply a more flexible mobile service. We believe this market will grow for all participants as UK health services delivery, including diagnostics, is delivered through partnerships and innovative third party solutions."


The Directors of the Company accept responsibility for the contents of this announcement.


For further information:

George Thomas

Chief Executive Officer

Goodbody Health Limited

+44 (0) 20 7971 1255

Anne Tew

Company Secretary

Goodbody Health Limited

+44 (0) 20 7971 1255



AQSE Corporate Adviser

Peterhouse Capital Limited

Guy Miller/Mark Anwyl

+44 (0) 20 7469 0930

Notes to Editors:

Goodbody Health Limited (AQSE: GDBY and OTCQB: GDBYF) is an aggregator of the highest quality, most innovative range of health and wellness services and products using the latest technology.  With over 52 products today, tests include blood, genetic, covid and other diagnostic solutions to meet today's fast evolving consumer expectations with more than 200,000 tests completed to date. A comprehensive portfolio of CBD based products complement the wellness range.

Goodbody Health, as a trusted distributor and retailer of accredited wellness products and diagnostic services, provides a unique 'frontline' healthcare service in the local community with expertise to enable customers to manage their health care digitally and make considered choices for their 'health span'. Our products and services grow local level amenities through a network of over 200 independent community providers offering much needed revenue to pharmacists and others local providers, while alleviating pressure on the NHS.

Datar Cancer Genetics is a global oncology research and applications company that is spearheading the development of non-invasive technologies for improved detection, treatment and management of cancer. The Company's state-of-the-art cancer research centre is NABL, ISO, CAP and CLIA accredited. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India. The Company has modern cancer research facilities in the US, UK, and India.

Website and social media links:




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.